CAR-NK-92 cells based on CD28-CD3ζ signaling domain have anti-tumor cytotoxicity targeting EpCAM and ErB2 breast cancer cells, EGFR on glioblastoma cells and breast cancer brain metastases, CD19 on B-cell malignancies, CS1 on multiple myeloma cells, and CD33 on acute myeloid leukemia cells [183]. This evidence concerns the gene CD28 and breast cancer.